Product
Suvecaltamide
1 clinical trial
2 indications
Indication
Parkinson's diseaseIndication
TremorClinical trial
A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants With Parkinson's DiseaseStatus: Recruiting, Estimated PCD: 2024-12-31